Emory reports successes in angioplasty to American Heart Association: lower risk, lower cost, improved outcomes

November 14, 2000

In 1980, Emory University Hospital became a pioneer of coronary angioplasty -- the less-invasive alternative to coronary bypass surgery in which catheters are used to improve blood flow to the heart.

Twenty years and 34,508 coronary angioplasties later, the success rate of angioplasty at Emory has progressively increased, despite an older and sicker patient population with more complex coronary problems.

John S. Douglas, Jr., M.D., director of coronary intervention at Emory University Hospital and one of the most experienced interventional cardiologists in the world, will present data from Emory's 20-year experience with angioplasty Wednesday morning at the 73rd meeting of the American Heart Association in New Orleans Nov. 12-15.

"In our experience from 1980 through 1999, the success rate of angioplasty has progressively increased, while the risk of needing bypass surgery or of a heart attack complicating the procedure has decreased," Dr. Douglas notes. "We also have observed a decrease in the length of time patients must stay in the hospital, which, along with reduced complications, has a major impact on cost."

These successes have been realized despite an increasingly difficult patient population. Over time, Dr. Douglas points out, the patient population needing angioplasties has become generally older, more patients have had prior heart attacks or have impaired heart function, and more patients have long-segment narrowing of the arteries. In addition, 26% of patients needing coronary angioplasty also have diabetes.

Since he began performing coronary angioplasty in 1980, Dr. Douglas, who is a professor of medicine in Emory University School of Medicine, has earned international recognition for his expertise in the field he helped launch and has served on the American College of Cardiology committee that established recommendations for the development and maintenance of competency in coronary interventional procedures.

Dr. Douglas' research has focused on improving the results of angioplasty by using stents, new antithrombotic agents and intracoronary radiation and by developing methods to protect the myocardium (thickest part of the heart wall) from tiny blood clots.

The Andreas Gruentzig Cardiovascular Center at Emory University Hospital was established in 1985 following the untimely death of Dr. Gruentzig, the first director of Emory's interventional cardiology program. Since its creation, the Gruentzig Center has fostered numerous innovations, including the first coronary stent to be placed in a human in the U.S. The center also conducted the largest single-center study to compare angioplasty and coronary bypass surgery and performed the first studies of the use of beta radiation to prevent restenosis (renarrowing) after angioplasty.

"We always have ongoing clinical trials to investigate new strategies to improve patient outcomes," Dr. Douglas explains. "The goal is to make coronary intervention safer and more durable. This retrospective of our 20-year experience shows that we are doing just that."
Media Contacts:
Holly Korschun, 404/727-3990 -- hkorsch@emory.edu
Sarah Goodwin, 404/727-3366 -- sgoodwi@emory.edu
Kathi Ovnic, 404/727-9371 -- covnic@emory.edu

Emory University Health Sciences Center

Related Angioplasty Articles from Brightsurf:

Ticagrelor was not superior to clopidogrel to reduce heart attack risk during angioplasty
A new study found the rate of heart attack and severe complications before, during or soon after elective surgery to open a blocked artery was similar between patients treated with clopidogrel and those who received the more potent antiplatelet medication ticagrelor.

Study finds significant variability in doctors' angioplasty death rates
Some doctors have higher or lower than expected death rates from coronary angioplasty procedures, also known as percutaneous coronary intervention (PCI); however, doctors should not be judged solely on the rate of patients who die from the procedure.

Beta-blockers following angioplasty show little benefit for some older patients
Following coronary angioplasty, beta-blockers did not significantly improve mortality rates or reduce the number of future cardiovascular incidents for older patients with stable angina but no history of heart attack or heart failure, according to a study published today in the JACC: Cardiovascular Interventions.

Sleep disorders may predict heart events after angioplasty
People who have had procedures to open blocked heart arteries after acute coronary syndrome (ACS) may have a higher risk of death, heart failure, heart attack and stroke if they have sleep disorders, such as sleep apnea, compared to those who don't.

Reasons for hospital-level variations in bleeding post-angioplasty are unclear
The use of bleeding avoidance strategies has only a modest effect on the variation in bleeding rates post-angioplasty among hospitals performing this procedure, leaving about 70 percent of the causes for this variation unexplained, according to a study published today in JACC: Cardiovascular Interventions.

US prediction models for kidney injury following angioplasty hold up in Japan
Models developed by the American College of Cardiology NCDR CathPCI Registry to predict the likelihood of angioplasty patients developing acute kidney injury and acute kidney injury requiring dialysis have proven to be effective among patients in Japan.

IV beta blockers before angioplasty are safe, but offer no clinical benefit
Giving intravenous beta blockers before performing a coronary angioplasty in patients who had experienced the deadliest form of heart attack -- ST-segment elevation myocardial infarction (STEMI) -- was safe but did not reduce heart attack severity or improve blood flow from the heart's main pumping chamber, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

Life-threatening bowel ischemia can often be treated by balloon angioplasty
Acute mesenteric ischemia (AMI) can be successfully treated with endovascular therapy such as balloon angioplasty, according to research from the University of Eastern Finland.

Radial access used less than femoral approach for emergency angioplasty
Although using the radial artery as the access point for angioplasty has been linked to reduced bleeding compared to use of the femoral artery, only a small number of high-risk heart attack patients who undergo rescue angioplasty -- emergency procedures following failed therapy with clot-busting drugs -- are treated by radial access, according to a study published today in the Journal of the American College of Cardiology: Cardiovascular Interventions.

Use of rarely appropriate angioplasty procedures declined sharply
The number of angioplasty procedures classified as rarely appropriate declined sharply between 2010 and 2014, as did the number of those performed on patients with non-acute conditions, according to a study published today in the Journal of the American Medical Association and simultaneously presented at a meeting of the American Heart Association in Orlando.

Read More: Angioplasty News and Angioplasty Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.